Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study

Cancers

Serena Di Cosimo¹  Angelo Olgiati²  Marco Danova²  Federica D’Antonio³  PaoloAndrea Zucali³  Mariangela Manzoni⁴  Francesco Grossi⁵  Filippo Pietrantonio⁶  Alessandra Raimondi⁶  Giordano Beretta⁷  Daniele Generali⁸  Fabiola Giudici⁸  Ottavia Bernocchi⁸  Nicla La Verde⁹  Elena Verri^1,10  Franco Nolè^1,10  Gabriella Farina^1,11  Francesco Agustoni^1,12  Angioletta Lasagna^1,12  Andrea Luciani^1,13  Karen Borgonovo^1,13  Monica Giordano^1,14  Giovanna Luchena^1,14  Giovanna Catania^1,15  Alberto Zaniboni^1,16  Antonio Bernardo^1,17  Emanuela Balletti^1,17  Barbara Tagliaferri^1,17  Guido Poggi^1,18  Benedetta Montagna^1,18  Irene Rampinelli^1,19  Massimo Di Maio^2,20  Laura Palmeri^2,21 

[1] Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy;Department of Internal Medicine and Oncology, ASST di Pavia, 27100 Pavia, Italy;Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, 20089 Rozzano, Italy;Department of Medical Oncology, Azienda Ospedaliera “Ospedale Maggiore”, 26013 Crema, Italy;Department of Medical Oncology, Fondazione IRCCS Ca’Grande Ospedale Maggiore Policlinico, 20162 Milano, Italy;Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy;Department of Medical Oncology, Humanitas Gavezzani, 24125 Bergamo, Italy;Department of Medical, Surgery and Health Sciences, University of Trieste, 34123 Trieste, Italy;Department of Oncology, Luigi Sacco Hospital-ASST Fatebenefratelli Sacco, Via G.B. Grassi 74, 20157 Milan, Italy;Division of Urogenital and Head & Neck Tumors, European Institute of Oncology (IEO) IRCCS, 20122 Milano, Italy;Medical Oncology Department, ASST Fatebenefratelli-Sacco, 20146 Milano, Italy;Medical Oncology Department, Fondazione IRCCS Policlinico “San Matteo”, 27100 Pavia, Italy;Medical Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, Bergamo, Italy;Medical Oncology Unit, ASST-Lariana, 22100 Como, Italy;Medical Oncology Unit, Azienda Ospedaliera Carlo Poma, 46100 Mantova, Italy;Medical Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, Italy;Medical Oncology Unit, ICS Maugeri-IRCCS, 27100 Pavia, Italy;Medical Oncology Unit, Institute of Care Città di Pavia, 27100 Pavia, Italy;Medical Oncology Unit, Multimedica Castellanza, 21010 Varese, Italy;Medical Oncology Unit, Ordine Mauriziano Hospital, 10128 Torino, Italy;Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20121 Milano, Italy;

关键词: cancer;    COVID-19;    SARS-CoV-2;    systemic anti-cancer treatment;    mortality;   

DOI  :  10.3390/cancers13061324

来源: DOAJ

【 摘 要 】

Cancer patients may be at high risk of infection and poor outcomes related to SARS-CoV-2. Analyzing their prognosis, examining the effects of baseline characteristics and systemic anti-cancer active therapy (SACT) are critical to their management through the evolving COVID-19 pandemic. The AIOM-L CORONA was a multicenter, observational, ambispective, cohort study, with the intended participation of 26 centers in the Lombardy region (Italy). A total of 231 cases were included between March and September 2020. The median age was 68 years; 151 patients (62.2%) were receiving SACT, mostly chemotherapy. During a median follow-up of 138 days (range 12–218), 93 events occurred. Age ≥60 years, metastatic dissemination, dyspnea, desaturation, and interstitial pneumonia were all independent mortality predictors. Overall SACT had a neutral effect (Odds Ratio [OR] 0.83, 95%Confidence Interval [95%CI] 0.32–2.15); however, metastatic patients receiving SACT were less likely to die as compared to untreated counterparts, after adjusting for other confounding variables (OR 0.23, 95%CI 0.11–0.51, p < 0.001). Among cancer patients infected by SARS-CoV-2, those with metastases were most at risk of death, especially in the absence of SACT. During the ongoing pandemic, these vulnerable patients should avoid exposure to SARS-CoV-2, while treatment adjustments and prioritizing vaccination are being considered according to international recommendations.

【 授权许可】

Unknown